- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07814274
Prospective Intestinal Ultrasound Study for Artificial Intelligence Algorithm Development (PSIUSAD)
Prospective Study for Intestinal Ultrasound Algorithm Development
This observational study will use intestinal ultrasound images to help develop computer programs that may make it easier to assess bowel inflammation.
The study will include adults who are healthy or who are having an intestinal ultrasound as part of care for inflammatory bowel disease, such as Crohn disease or ulcerative colitis. Researchers want to find out whether a computer program can measure bowel wall thickness from ultrasound images as accurately as experienced ultrasound clinicians. They will also explore whether the program can identify other changes in the bowel.
Participants will have an intestinal ultrasound as part of their usual care. People who agree to take part will allow the research team to use de-identified ultrasound images and a small amount of related health information. No medication, experimental treatment, or additional ultrasound procedure will be given for this study. The computer program will not be used to make decisions about a participant's care, and participants will not receive individual results from the program.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Inflammatory bowel disease, including Crohn disease and ulcerative colitis, requires reliable assessment of intestinal inflammation to support clinical monitoring and treatment decisions. Intestinal ultrasound is a non-invasive, point-of-care imaging method that can assess bowel inflammation without radiation exposure. However, its interpretation may vary by operator experience and local scanning practice.
This prospective, multicentre, observational study will collect de-identified intestinal ultrasound images, cine loops, and limited associated metadata from adults aged 18 years and older. Eligible participants may be healthy individuals with no known inflammatory bowel disease or individuals undergoing intestinal ultrasound for inflammatory bowel disease screening, monitoring, or another clinical reason. Intestinal ultrasound examinations will be performed as part of routine clinical care. The study does not add a treatment intervention, investigational drug, experimental device, or clinically directed diagnostic procedure.
Following informed consent, ultrasound images and cine loops generated during the routine examination will be exported in de-identified DICOM format. Limited information relevant to artificial intelligence development and validation, such as age, sex, self-reported race, pregnancy status, eligibility confirmation, and relevant scan-related or pre-existing clinical information, may also be recorded. Direct personal identifiers and personal health information will be removed before the data are transferred outside the clinical site.
The de-identified data will be reviewed for appropriate de-identification and formatting before secure transfer to Dova Health Intelligence Inc. The data will be annotated and used to develop, train, tune, and test computer vision algorithms designed to identify bowel structures and measure bowel wall thickness on intestinal ultrasound. The study will also assess the feasibility of developing algorithms to evaluate bowel wall layer stratification, luminal diameter, bowel wall flow, bowel wall scarring, gastrointestinal motility, and mesenteric fat proliferation.
The primary objective is to evaluate whether the computer vision algorithm prototype can measure bowel wall thickness with performance comparable to manual measurements by experienced sonographers. Secondary objectives include evaluating the quality, diversity, and usability of the collected ultrasound data for artificial intelligence development and assessing the feasibility of measuring additional intestinal ultrasound features.
The algorithms developed in this study are investigational and will not be used in routine clinical care during the study. No participant-level algorithm findings will be returned to participants, and participation is not expected to provide a direct clinical benefit. The primary foreseeable risk is a loss of confidentiality; this risk is mitigated through de-identification at the study site, verification of de-identification before transfer, secure file transfer, controlled access, and secure cloud-based storage. The study plans to enroll up to 95 participants internationally, including up to 30 participants at the British Columbia site.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Cristian A Massaro, MSc
- Número de telefone: 587-223-5248
- E-mail: iusresearch@ibdcentrebc.ca
Locais de estudo
-
-
British Columbia
-
Vancouver, British Columbia, Canadá, V6Z 2L2
- IBD Centre of BC
-
Contato:
- Cristian A Massaro, MSc
- Número de telefone: 587-223-5248
- E-mail: iusresearch@ibdcentrebc.ca
-
Investigador principal:
- Matthew J Smyth, MD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Adults aged 18 years or older.
- Individuals who are either healthy with no known finding of inflammatory bowel disease before the ultrasound examination or undergoing intestinal ultrasound for inflammatory bowel disease screening, monitoring, or another clinical reason.
- Individuals who are able and willing to provide informed consent for the collection and use of de-identified study data.
Exclusion Criteria:
- Individuals who do not meet the study demographic requirements.
- Individuals unable or unwilling to provide informed consent.
- Pregnant individuals.
- Individuals with health conditions managed using drugs or medical-device intervention, or with unmanaged conditions or conditions requiring monitoring, that could affect study eligibility or the ultrasound assessment.
- Individuals who have recently taken contrast-enhancing compounds.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Intestinal Ultrasound Participants
This cohort includes adults aged 18 years and older who are either healthy or undergoing intestinal ultrasound for inflammatory bowel disease screening, monitoring, or another clinical reason.
Participants will undergo intestinal ultrasound as part of routine clinical care.
With informed consent, de-identified ultrasound images and cine loops, along with limited associated information such as age, sex, self-reported race, and relevant scan-related details, will be collected for artificial intelligence algorithm development.
No study drug, experimental treatment, or experimental device will be administered.
The artificial intelligence algorithms will not be used to guide participant care or provide individual diagnostic results during the study.
|
Intestinal ultrasound images and cine loops will be collected from adults undergoing ultrasound as part of routine clinical care.
Following informed consent, the images and cine loops will be de-identified and used for artificial intelligence algorithm development, training, tuning, and testing.
The study does not assign participants to receive an intervention, and the ultrasound is not performed solely for research purposes.
The artificial intelligence algorithms developed using the data will not be used to guide participant care or provide individual diagnostic results during the study.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Artificial Intelligence-Generated Bowel Wall Thickness Measurement Agreement
Prazo: Day 1, after completion of the intestinal ultrasound examination
|
Agreement between bowel wall thickness measurements generated by the artificial intelligence computer-vision algorithm and manual bowel wall thickness measurements performed by experienced sonographers using de-identified intestinal ultrasound images and cine loops.
Agreement will be assessed using the pre-specified performance metric in the statistical analysis plan.
|
Day 1, after completion of the intestinal ultrasound examination
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Bowel Wall Layer Stratification Feasibility
Prazo: Day 1, after completion of the intestinal ultrasound examination
|
Proportion of de-identified intestinal ultrasound images and cine loops for which the artificial intelligence algorithm generates an interpretable bowel wall layer stratification.
|
Day 1, after completion of the intestinal ultrasound examination
|
|
Luminal Diameter Measurement Feasibility
Prazo: Day 1, after completion of the intestinal ultrasound examination
|
Proportion of de-identified intestinal ultrasound images and cine loops for which the artificial intelligence algorithm generates an interpretable luminal diameter measurement.
|
Day 1, after completion of the intestinal ultrasound examination
|
|
Bowel Wall Flow Assessment Feasibility
Prazo: Day 1, after completion of the intestinal ultrasound examination
|
Proportion of de-identified intestinal ultrasound images and cine loops for which the artificial intelligence algorithm generates an interpretable bowel wall flow assessment.
|
Day 1, after completion of the intestinal ultrasound examination
|
|
Bowel Wall Scarring Assessment Feasibility
Prazo: Day 1, after completion of the intestinal ultrasound examination
|
Proportion of de-identified intestinal ultrasound images and cine loops for which the artificial intelligence algorithm generates an interpretable bowel wall scarring assessment.
|
Day 1, after completion of the intestinal ultrasound examination
|
|
Gastrointestinal Motility Assessment Feasibility
Prazo: Day 1, after completion of the intestinal ultrasound examination
|
Proportion of de-identified intestinal ultrasound images and cine loops for which the artificial intelligence algorithm generates an interpretable gastrointestinal motility assessment.
|
Day 1, after completion of the intestinal ultrasound examination
|
|
Mesenteric Fat Proliferation Assessment Feasibility
Prazo: Day 1, after completion of the intestinal ultrasound examination
|
Proportion of de-identified intestinal ultrasound images and cine loops for which the artificial intelligence algorithm generates an interpretable assessment of mesenteric fat proliferation.
|
Day 1, after completion of the intestinal ultrasound examination
|
|
Proportion of Cine Loops Suitable for AI Development
Prazo: At completion of dataset preparation
|
Percentage of collected de-identified cine loops that meet all pre-specified completeness, image-quality, and required-metadata criteria for artificial intelligence algorithm training, tuning, and testing.
|
At completion of dataset preparation
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Matthew J Smyth, MD, University of British Columbia, IBD Centre of BC
Publicações e links úteis
Publicações Gerais
- Novak KL, Nylund K, Maaser C, Petersen F, Kucharzik T, Lu C, Allocca M, Maconi G, de Voogd F, Christensen B, Vaughan R, Palmela C, Carter D, Wilkens R. Expert Consensus on Optimal Acquisition and Development of the International Bowel Ultrasound Segmental Activity Score [IBUS-SAS]: A Reliability and Inter-rater Variability Study on Intestinal Ultrasonography in Crohn's Disease. J Crohns Colitis. 2021 Apr 6;15(4):609-616. doi: 10.1093/ecco-jcc/jjaa216.
- Goodsall TM, Nguyen TM, Parker CE, Ma C, Andrews JM, Jairath V, Bryant RV. Systematic Review: Gastrointestinal Ultrasound Scoring Indices for Inflammatory Bowel Disease. J Crohns Colitis. 2021 Jan 13;15(1):125-142. doi: 10.1093/ecco-jcc/jjaa129.
- Jauregui-Amezaga A, Rimola J. Role of Intestinal Ultrasound in the Management of Patients with Inflammatory Bowel Disease. Life (Basel). 2021 Jun 23;11(7):603. doi: 10.3390/life11070603.
- Frias-Gomes C, Torres J, Palmela C. Intestinal Ultrasound in Inflammatory Bowel Disease: A Valuable and Increasingly Important Tool. GE Port J Gastroenterol. 2021 Nov 23;29(4):223-239. doi: 10.1159/000520212. eCollection 2022 Jul.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- H26-00188
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .